Notes for P&L
All amounts in SEKm unless otherwise stated
Note 6 Segment reporting
The division into business areas reflects AddLife’s internal organisation and reporting system. Operating segments are reported in a manner consistent with AddLife's internal reporting, which is submitted to the CEO, who has been identified as the highest executive within AddLife. AddLife reports business areas as an operating segment. AddLife reports its business areas as operating segments. The two business areas are Labtech and Medtech. This market grouping reflects a natural division of the Life Science market. AddLife uses EBITA (see definitions) as a performance measure when monitoring the business areas. Intra-Group sales are based on the same prices that an independent party would pay for the product.
Labtech
The companies in the Labtech business area operate within diagnostics and biomedical research, as well as laboratory analysis. The companies deliver directly to customers various products and solutions that include analytical instruments, equipment, microscopes, consumables and reagents, as well as software support and technical service, primarily to laboratories in medicine, research, academia and the food and pharmaceutical industries. The companies within the Labtech business area are mainly active in microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics and in the food industry. Customers are also offered training programmes in various areas to ensure that customers have the appropriate skills and to maximise user benefit for the products the Company provides.
Medtech
The companies in the Medtech business area provide medical device products within the medtech market, with a focus on surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare.
Data by operating segment
| 2022 | 2021 | |||
|---|---|---|---|---|
| Net sales | Externally | Externally | ||
| Medtech | 5,210 | 3,625 | ||
| Labtech | 3,880 | 4,373 | ||
| Group items | -6 | -5 | ||
| Total | 9,084 | 7,993 | ||
| 2022 | 2021 | |||
| EBITA | EBITA | EBITA margin, % |
EBITA | EBITA margin, % |
| Medtech | 573 | 11.0 | 310 | 8.6 |
| Labtech | 667 | 17.2 | 977 | 22.3 |
| Group items | -19 | -14 | ||
| Total | 1,221 | 1,273 | ||
| 2022 | 2021 | |||||
|---|---|---|---|---|---|---|
| Operating profit/loss, assets and liabilities | Operating profit | Assets¹ | Liabilities¹ | Operating profit | Assets¹ | Liabilities¹ |
| Medtech | 228 | 10,231 | 1,416 | 85 | 8,127 | 941 |
| Labtech | 601 | 2,312 | 887 | 927 | 2,090 | 838 |
| Group items | -21 | 514 | 5,783 | -16 | 379 | 4,526 |
| Total | 808 | 13,057 | 8,086 | 996 | 10,596 | 6,305 |
| Finance income and costs | -206 | -69 | ||||
| Profit before taxes | 602 | 927 | ||||
| ¹ Does not include balances in Group accounts or financial transactions with Group companies. | ||||||
| 2022 | 2021 | |||||
|---|---|---|---|---|---|---|
| Investments in non-current assets | Intangible | Property, plant and equipment¹ | Total | Intangible | Property, plant and equipment¹ | Total |
| Medtech | 517 | 242 | 759 | 1,826 | 234 | 2,060 |
| Labtech | 127 | 108 | 235 | 133 | 96 | 229 |
| Group items | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 644 | 350 | 994 | 1,959 | 330 | 2,289 |
| ¹ The amounts do not include the effects of corporate acquisitions. | ||||||
| 2022 | 2021 | |||||
| Depreciation/amortisation of non-current assets | Intangible | Property, plant and equipment¹ | Total | Intangible | Property, plant and equipment¹ | Total |
| Medtech | -345 | -199 | -544 | -225 | -102 | -327 |
| Labtech | -66 | -107 | -173 | -50 | -97 | -147 |
| Group items | -2 | -3 | -5 | -2 | -3 | -5 |
| Total | -413 | -309 | -722 | -277 | -202 | -479 |
| ¹ Depreciation/amortisation of property, plant and equipment include depreciation/amortisation of right- of-use assets. | ||||||
| Significant profit or loss items, other than depreciation or amortisation, not matched by payments | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2022 | 2021 | |||||||
| Capital gains | Change in pension liability | Other items | Total | Capital gains | Change in pension liability | Other items | Total | |
| Medtech | 1 | -2 | -118 | -119 | -2 | -1 | 0 | -3 |
| Labtech | -3 | -2 | -22 | -27 | -1 | -1 | -6 | -8 |
| Group items | – | – | 105 | 105 | – | – | -22 | -22 |
| Total | -2 | -4 | -35 | -41 | -3 | -2 | -28 | -33 |
| 2022 | 2021 | |||||
|---|---|---|---|---|---|---|
| Data by country | Net sales external | Assets¹ | Of which non-current assets | Net sales external | Assets¹ | Of which non-current assets |
| Sweden | 1,100 | 1,590 | 1,116 | 1,141 | 1,465 | 1,081 |
| Denmark | 956 | 650 | 405 | 1,158 | 682 | 398 |
| Finland | 582 | 299 | 129 | 648 | 260 | 131 |
| Norway | 876 | 515 | 292 | 1,009 | 484 | 280 |
| Ireland | 892 | 3,580 | 3,200 | 582 | 3,273 | 2,959 |
| Spain | 725 | 1,339 | 835 | – | – | – |
| UK | 980 | 385 | 83 | 620 | 340 | 58 |
| Germany | 357 | 2,454 | 2,321 | 480 | 2,119 | 2,020 |
| Other countries | 2,616 | 1,895 | 951 | 2,355 | 1,885 | 891 |
| Group items and unallocated assets | – | 350 | 153 | – | 88 | 27 |
| Total | 9,084 | 13,057 | 9,485 | 7,993 | 10,596 | 7,845 |
| ¹ Does not include balances in Group accounts and financial assets. External net sales are based on the customers' location, and the carrying amounts of assets are based on where the assets are located. | ||||||
| 2022 | 2021 | |||||
| Investments in non-current assets | Intangible | Property, plant and equipment | Total | Intangible | Property, plant and equipment | Total |
| Sweden | 100 | 40 | 140 | 46 | 21 | 67 |
| Denmark | 1 | 16 | 17 | 82 | 11 | 93 |
| Finland | 0 | 7 | 7 | 3 | 22 | 25 |
| Norway | 10 | 42 | 52 | 7 | 16 | 23 |
| Ireland | 31 | 23 | 54 | 876 | 110 | 986 |
| Spain | 406 | 68 | 474 | – | – | – |
| UK | 3 | 51 | 54 | 0 | 64 | 64 |
| Germany | 85 | 9 | 94 | 823 | 13 | 836 |
| Other countries | 8 | 94 | 102 | 122 | 73 | 195 |
| Total | 644 | 350 | 994 | 1,959 | 330 | 2,289 |
| The Group has no single customer whose revenues account for 10 percent of total revenue, for which reason there is no related reporting. | ||||||